Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
66 studies found for:    myeloma AND (women OR woman OR female)
Show Display Options
Rank Status Study
21 Recruiting A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Sotatercept;   Drug: Placebo
22 Active, not recruiting Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Conditions: Breast Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Musculoskeletal Complications;   Pain;   Prostate Cancer;   Urinary Complications
Intervention: Drug: zoledronic acid
23 Active, not recruiting
Has Results
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: filgrastim;   Biological: sargramostim;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: melphalan;   Drug: prednisone;   Drug: thalidomide;   Procedure: peripheral blood stem cell transplantation
24 Recruiting Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study
Condition: Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation
Intervention: Drug: Bortezomib
25 Completed ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain
Conditions: Bone Metastases;   Multiple Myeloma
Interventions: Device: ExAblate 2000;   Device: Sham
26 Recruiting Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
27 Terminated Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.
Conditions: Vertebral Fracture;   Multiple Myeloma;   Osteolytic Metastases
Intervention: Device: balloon kyphoplasty
28 Active, not recruiting Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Relapsed Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: CC-5013
29 Completed A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
Conditions: Lymphoma, Mantle-cell;   Leukemia, Lymphocytic, Chronic, B-Cell;   Leukemia, Hairy Cell;   Waldenstrom Macroglobulinemia;   Multiple Myeloma
Intervention: Drug: ON01910 Na
30 Active, not recruiting Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: bortezomib
31 Recruiting Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
Conditions: Relapsed Multiple Myeloma;   End-stage Renal Disease
Intervention: Drug: Carfilzomib
32 Completed Protein Tyrosine Kinases (PTK) in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: PTK787/ZK222584
33 Active, not recruiting Agriculture Health Study
Conditions: Prostate Cancer;   Pesticide Exposure;   Lymphoma;   Multiple Myeloma
Intervention:
34 Recruiting Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
Conditions: Acute Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
Intervention: Genetic: cytogenetic analysis
35 Active, not recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Drug: CT-011;   Biological: Dendritic Cell Fusion Vaccine
36 Not yet recruiting Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
Condition: Multiple Myeloma
Intervention: Drug: Lenalidomide
37 Completed RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: RAD001;   Drug: lenalidomide
38 Recruiting Preservation of Ovarian Function After Hematopoietic Cell Transplant
Conditions: Multiple Myeloma;   Non-Hodgkin Lymphoma;   Hodgkin Disease;   Acute Myeloid Leukemia;   Myeloproliferative Disorders
Interventions: Drug: Leuprolide;   Biological: hematopoietic cell transplant;   Biological: reduced intensity allogeneic HCT
39 Recruiting Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Plerixafor (AMD3100);   Drug: bortezomib
40 Active, not recruiting
Has Results
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years